Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Graviton Bioscience Corporation, a clinical-stage biotechnology company developing selective ROCK2 inhibitors for metabolic, inflammatory, fibrotic, and central nervous system disorders, among other therapeutic indications, today announced that Samuel Waksal, Ph.D., Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore HealthCONx Conference.

PRNewsWire • Nov 20, 2025

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

LONDON and NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced financial and operational results for the third quarter ended September 30, 2025, and provided a corporate update.

GlobeNewsWire • Nov 13, 2025

MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Lags Revenue Estimates

MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.54 per share a year ago.

Zacks Investment Research • Nov 13, 2025

MeiraGTx: Latest Eli Lilly Partnership Ignites Riboswitch Technology Potential

MeiraGTx Holdings plc secures a transformative partnership with Eli Lilly, granting worldwide rights to its AAV-AIPL1 gene therapy for LCA4. MGTX receives $75 million upfront, up to $400 million in milestones, and tiered royalties, strengthening its financial position and reducing near-term dilution risk. The company's riboswitch technology and multiple collaborations, including with Johnson & Johnson and Hologen, highlight its innovation and diversified pipeline.

Seeking Alpha • Nov 12, 2025

Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease

MeiraGTx Holdings has signed a deal with Eli Lilly , potentially worth over $475 million, granting the pharma giant rights to its experimental gene therapy for a rare, inherited disorder that causes severe vision loss from birth.

Reuters • Nov 10, 2025

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration in the area of ophthalmology with Eli Lilly and Company (“Lilly”).

GlobeNewsWire • Nov 10, 2025

MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

MeiraGTx (MGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Nov 5, 2025

MeiraGTx (MGTX) Moves 12.4% Higher: Will This Strength Last?

MeiraGTx (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Investment Research • Oct 22, 2025

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

LONDON and NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will exhibit two posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress, which is being held from October 7-10, 2025, in Seville, Spain. The posters are available on the Posters and Publications page of the Company's website.

GlobeNewsWire • Oct 7, 2025

MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy Vital

MeiraGTx is a clinical-stage gene therapy biotech with end-to-end GMP. Its late-stage assets include AAV-AIPL1, AAV-AQP1, and Bota-Vec. AAV-AQP1 is in pivotal Phase 2 trials under the FDA's RMAT designation for radiation-induced xerostomia. MGTX anticipates its BLA by 2026. I believe their Hologen partnership for PD is MGTX's main value driver. This should fund AAV-GAD through Phase 3 and commercialization if successful.

Seeking Alpha • Sep 25, 2025